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A 64-year-old man suﬀering polyarthralgia and bone pain was referred to our hospital.  Renal dys-
function,  hypophosphatemia and increased levels of bone alkaline phosphatase were found.  The 
patientʼs serum creatinine level had gradually increased after the initiation of adefovir dipivoxil 
administration for hepatitis B.  In agreement with multifocal uptakes of bone scintigraphy,  iliac bone 
biopsy revealed an abnormal increase in osteoid tissues.  Reducing the dose of adefovir and initiating 
the administration of eldecalcitol were eﬀective for reducing proteinuria and glucosuria,  and for 
ameliorating bone pain with an increase in serum phosphate level.  This case ﬁrst showed a clinical 
course of hypophosphatemic osteomalacia caused by secondary Fanconiʼs syndrome for 8 years after 
adefovir administration.  Early diagnosis is important for the reversibility of bone damage and for a 
better renal prognosis.
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e present here an interesting case of severe 
bone pain,  polyarthralgia and immobility due to 
osteomalacia caused by drug-induced renal tubular 
dysfunction.  There has been a recent increase in 
reports regarding bone damage due to renal complica-
tions of anti-viral drugs [1-3],  however,  to the best 
of our knowledge,  no detailed clinical course of the 
progress of renal dysfunction and bone malformation 
has yet been described.  We present here a case of 
systemic pain due to hypophosphatemic osteomalacia 
caused by adefovir dipivoxil (ADV)-related renal insuf-
ﬁciency,  in which laboratory data for 8 years after the 
initiation of ADV were successfully pursued.
Case Presentation
　 A 64-year-old Japanese man who had suﬀered 
systemic polyarthralgia and bone pain was referred to 
our hospital (Fig.  1,  upper panel).  The cause of his 
persistent back pain had not been determined by regu-
lar checkups at other hospitals.  The patient had been 
taking oral ADV (10mg/day) and lamivudine (100mg/
day) to treat chronic hepatitis due to hepatitis B virus 
(HBV) hepatitis B surface antigen (HBsAg) was posi-
tive but neither HBs-antibody nor HBV-DNA was 
detected in his serum at the ﬁrst visit.  A detailed 
medical interview revealed that his lower back pain 
had deteriorated over a 3-year period of ADV admin-
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Fig. 1　 Clinical course after ADV treatment.  Chest X-ray,  bone scintigraphy and pathologi-
cal ﬁndings of iliac bone biopsy with Villanueva-Goldner staining are shown.
istration.  He had also suﬀered bilateral hip joint pain,  
and the area of continuing pain had been spreading to 
his whole body including his shoulders,  thorax,  hip 
and knee joints.  Gait disturbance and systemic polyar-
thralgia had also gradually progressed over the 
3-year period.  When the patient visited our hospital,  
his symptoms suggested ankylosing spondylitis since it 
was diﬃcult for him to stretch his back and he was 
unable to bend his back even slightly due to his severe 
polyarthralgia and continuing bone pain.  A laboratory 
workup showed renal dysfunction (creatinine,  
1.29mg/dl; normal: 0.6-1.1; and estimated glomeru-
lar ﬁltration rate,  44.5ml/min/1.73m2),  hypophos-
phatemia (1.4mg/dl,  normal: 2.5-4.6),  but normocal-
cemia (8.8mg/dl,  normal: 8.6-10.1),  and increased 
levels of alkaline phosphatase (ALP; 1,314IU/l,  
normal: 110-360) and bone ALP (BAP; 116IU/l,  
normal: 13-34) (Fig.  1,  upper panel).  Serum C-reactive 
protein,  rheumatoid factor,  anti-cyclic citrullinated 
peptide antibody and anti-nuclear factor were negative,  
and no consumption of serum complements was shown.  
The patientʼs level of renal tubular reabsorption of 
phosphate (ｵTRP) was extremely low at 30.9ｵ 
(normal: 82-95ｵ),  indicating impairment of renal 
absorption of inorganic phosphate.  Considering the 
complication of bone-related endocrine disorders that 
induce hypophosphatemia,  we measured serum levels 
of intact parathyroid hormone (PTH; 59pg/ml,  nor-
mal: 10-65) and PTH-related peptide (PTHrP;  
＜1.1pg/ml,  normal: ＜1.1),  both of which were within 
normal range.  Of note,  the patientʼs serum 1,25-dihy-
droxyvitamin D3 level was found to be low at 14.0pg/
ml (normal: 20-60),  possibly due to damage of the 
renal proximal tubules.  Arterial blood gas analysis 
showed severe metabolic acidosis (pH,  7.27; HCO3－,  
16.4mmol/l; serum potassium,  3.7mmol/l; base excess,  
－9.6mmol/l).  Tumor-induced hypophosphatemia was 
excluded because of the suppression of serum ﬁbro-
blast growth factor-23 (FGF-23; ＜1.0pg/ml,  nor-
mal: 10-50).  Urinalysis showed alkaluria (pH7.5),  
proteinuria (3＋),  glucosuria (3＋) and excess excretion 
of amino acids (Val,  4,002µmol/day; Ala,  16,916µmol/ 
day; Leu,  1,551µmol/day).  Urinary levels of N-acetyl-
glucosaminidase (26.4U/day) and β2-microglobulin 
(89.6mg/day) were also increased.  A chest X-ray 
revealed pseudofractures of the right ribs (Fig.  1,  
arrows in lower panel),  and bone scintigraphy using 
99mTc-hydroxymethylene diphosphonate showed multi-
focal uptake in both scapulae,  ribs,  femoral necks and 
knee joints,  indicating the presence of metabolic bone 
disease (Fig.  1,  arrowheads in lower panel).  Laboratory 
data including the patientʼs past data showed that his 
serum creatinine level had gradually increased over a 
period of 8 years after the initiation of oral ADV 
administration (Fig.  1,  upper panel).  Together with 
the advent of bone pain,  the patientʼs serum ALP 
level was also enhanced.  For the diagnosis of bone 
malformation,  iliac bone biopsy was performed,  and 
an abnormal increase in osteoid tissues was revealed 
by Villanueva-Goldner staining (Fig.  1,  lower panel).  
Based on these clinical and pathological ﬁndings,  we 
made a diagnosis of hypophosphatemic osteomalacia 
caused by secondary Fanconiʼs syndrome possibly due 
to ADV.  Since the complete cessation of ADV admin-
istration might cause a recurrence of acute hepatitis,  
we reduced the patientʼs daily dose from 10mg to 5mg 
based on a previous report showing that ADV reduc-
tion improved Fanconiʼs syndrome [4].  After this 
reduction,  the patientʼs proteinuria and glucosuria 
gradually improved over a period of 6 months.  For 
osteomalacia with accompanying hypophosphatemia,  
the patient was treated with oral eldecalcitol and 
bicarbonate,  resulting in an increase in his serum 
phosphate level (～2.4mg/dl) and ameliorating his 
systemic pain and arthralgia for 6 months.
Discussion
　 Approximately 40ｵ of patients with Fanconiʼs 
syndrome are complicated with secondary osteomalacia 
[5].  Some cases of Fanconiʼs syndrome are congenital,  
but most cases are caused by various nephrotoxic 
agents such as acetazolamide,  outdated tetracycline,  
aminoglycoside antibiotics,  valproate,  6-mercaptopu-
rine,  streptozotocin,  and ifosfamide [5].  Fanconiʼs 
syndrome includes dysfunction of the proximal tubular 
resorption of glucose,  phosphate and amino acids in 
the kidney.  ADV is used as an antiviral agent for the 
treatment of chronic hepatitis B and human immunode-
ﬁciency virus (HIV) infection.  ADV-induced nephro-
toxicity is generally caused by a high dose (60-
120mg/day) of ADV therapy for HIV infection,  
however,  it has recently been reported that the same 
complication can occur even with low-dose therapy for 
chronic hepatitis [1-3].  The underlying mechanism 
seems to be related to the preferential accumulation of 
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ADV in the proximal tubules via speciﬁc organic anion 
transporters [6] and the resultant depletion of mito-
chondrial DNA in the proximal tubular epithelium 
through its replicative inhibition,  leading to renal 
tubular damage [7,  8].  In the present case,  we 
judged that the onset of renal insuﬃciency occurred 
approximately 2 years after the commencement of 
ADV treatment,  and the subsequent bone malforma-
tion induced by hypophosphatemia appeared after 5 
years of ADV treatment.  The standard treatment for 
this complication is the cessation of ADV administra-
tion and supplementation of oral phosphate [1-3].  
However,  in the present case,  reducing ADV was 
eﬀective for inhibiting the progression of renal damage 
including proteinuria and glucosuria.  In addition,  the 
administration of eldecalcitol,  which is eﬀective not 
only for increasing calcium absorption from the gas-
trointestinal tract but also for inhibiting bone resorp-
tion [9,  10],  was eﬀective for this bone complication,  
ameliorating bone pain and increasing the patientʼs 
serum phosphate level.
　 Thus,  serum phosphorus and ALP levels should be 
examined in patients with systemic bone pain and/or 
persistent polyarthralgia,  and inorganic phosphate and 
ALP levels,  as well as urinalysis and renal function,  
should be regularly monitored in patients being treated 
with ADV.  With respect to Fanconiʼs syndrome caused 
by ADV,  abnormalities in urinalysis including those in 
urinary pH,  glucose and protein are most likely to be 
the earliest manifestations.  Early diagnosis of this 
complication through regular urinary checkups is 
extremely important for the reversibility of bone dam-
age and for a better renal prognosis.
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